Ret Proto-Oncogene anticorps (AA 702-848)

N° du produit ABIN6940508

L’anticorps Souris Monoclonal anti-Ret Proto-Oncogene a été validé pour ELISA et Coat. Il convient pour détecter Ret Proto-Oncogene dans des échantillons de Humain.

Aperçu rapide pour Ret Proto-Oncogene anticorps (AA 702-848) (ABIN6940508)

Antigène: Ret Proto-Oncogene (RET)

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Ret Proto-Oncogene est non-conjugé

Application: ELISA, Coating (Coat)

Clone: RET-2976

Détail du produit anti-Ret Proto-Oncogene anticorps

Épitope: AA 702-848

Purification: Purified by Protein A/G

Immunogène: Recombinant fragment (around aa 702-848) of human RET protein (exact sequence is proprietary)

Isotype: IgG1 kappa

Information d'application

Indications d'application:

Positive Control: Breast, Prostate or Colon Carcinoma.

Known Application: ELISA (For coating, order Ab without BSA)Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Stockage

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Date de péremption: 24 months

Détails sur Ret Proto-Oncogene

Antigène: Ret Proto-Oncogene (RET)

Autre désignation: RET

Sujet: The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system, in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney.Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease.

Poids moléculaire: 150kDa (precursor), 170kDa (Mature)

ID gène: 5979

UniProt: P07949

Pathways: Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation